Results 21 to 30 of about 272,115 (210)

Anti-VEGF reduces inflammatory features in macular edema secondary to retinal vein occlusion [PDF]

International Journal of Ophthalmology, 2022
AIM: To investigate the anti-inflammatory effect of intravitreal injection of anti-vascular endothelial growth factor (anti-VEGF) in patients with macular edema secondary to retinal vein occlusion (RVO-ME).
Hai-Feng Qin, Fan-Jun Shi, Chao-Yang Zhang, Da-Wei Luo, Shi-Yue Qin, Jing Wu, Hai Xie, Jing-Ting Zhang, Qing-Hua Qiu, Kun Liu, Guo-Tong Xu, Guo-Xu Xu, Jing-Fa Zhang   +12 more
doaj   +1 more source

Anti-VEGF– and anti-VEGF receptor–induced vascular alteration in mouse healthy tissues [PDF]

Proceedings of the National Academy of Sciences, 2013
Systemic therapy with anti-VEGF drugs such as bevacizumab is widely used for treatment of human patients with various solid tumors. However, systemic impacts of such drugs in host healthy vasculatures remain poorly understood. Here, we show that, in mice, systemic delivery of an anti-VEGF or an anti–VEGF receptor (VEGFR)-2 neutralizing antibody caused ...
Y. Yang, Y. Zhang, Z. Cao, H. Ji, X. Yang, H. Iwamoto, E. Wahlberg, T. Lanne, B. Sun, Y. Cao   +9 more
openaire   +2 more sources

Anti-VEGF Therapy and the Retina: An Update [PDF]

Journal of Ophthalmology, 2015
Ocular angiogenesis and macular oedema are major causes of sight loss across the world. Aberrant neovascularisation, which may arise secondary to numerous disease processes, can result in reduced vision as a result of oedema, haemorrhage, and scarring.
Tah, V, Orlans, H, Hyer, J, Casswell, E, Din, N, Sri Shanmuganathan, V, Ramskold, L, Pasu, S   +7 more
openaire   +4 more sources

Anti-vascular endothelial growth factor monotherapy or combined with verteporfin photodynamic therapy for retinal angiomatous proliferation: a systematic review with meta-analysis

Frontiers in Pharmacology, 2023
Purpose: To assess functional and anatomical outcomes of intravitreal anti-Vascular Endothelial Growth Factor (anti-VEGF) monotherapy versus combined with verteporfin Photodynamic Therapy (PDT) for Retinal Angiomatous Proliferation (RAP).Methods: Studies
Matteo Fallico, Iacopo Macchi, Andrea Maugeri, Giuliana Favara, Martina Barchitta, Roberta Magnano San Lio, Antonella Agodi, Andrea Russo, Antonio Longo, Teresio Avitabile, Niccolò Castellino, Michele Reibaldi, Francesco Pignatelli, Maria Vadalà, Clara Patanè, Marcella Nebbioso, Vincenza Bonfiglio   +16 more
doaj   +1 more source

Trends, geographical variation and factors associated with the use of anti-VEGF intravitreal injections in Portugal (2013–2018): a retrospective analysis of administrative data

BMJ Open, 2022
Aims The arrival of anti-vascular endothelial growth factor (anti-VEGF) therapies represented a treatment shift for several ophthalmological disorders and led to an increasing number of patients undergoing intravitreal injections.
Ana Patricia Marques, Rui Santana, António Filipe Macedo, Pedro Laires, João Victor Rocha, Marta Afonso-Silva, Ana Sofia Almeida, Julieta Fernandes, Marisa Pardal   +8 more
doaj   +1 more source

Morphologic Criteria of Lesion Activity in Neovascular Age-Related Macular Degeneration: A Consensus Article [PDF]

, 2017
Intravitreal antivascular endothelial growth factor drugs represent the current standard of care for neovascular age-related macular degeneration (nAMD).
Elena Gusson, Giacomo Panozzo, Giorgio Boschi, Giuseppe Scarpa, Nicola Zemella, null null, Sandro Saviano, Stefania Miotto, Stefano Piermarocchi   +8 more
core   +1 more source

The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy

Drugs in Context, 2018
Diabetes is a major cause of visual impairment among workingage adults in the United States. The proliferative form of diabetic retinopathy is associated with severe vision loss (acuity
Yue Zhao, Rishi P Singh
doaj   +1 more source

Widening use of dexamethasone implant for the treatment of macular edema [PDF]

, 2017
Sustained-release intravitreal 0.7 mg dexamethasone (DEX) implant is approved in Europe for the treatment of macular edema related to diabetic retinopathy, branch retinal vein occlusion, central retinal vein occlusion, and non-infectious uveitis.
Avitabile T., Bonfiglio V., Fallico M., Fichera S., Longo A., Macchi I., Pizzo A., Rapisarda C., Reibaldi M., Russo A.   +9 more
core   +2 more sources

The acute and chronic effects of intravitreal anti-vascular endothelial growth factor injections on intraocular pressure: A review [PDF]

, 2017
The acute and chronic effects of repeated intravitreal antivascular endothelial growth factor (VEGF) injections on intraocular pressure have not been fully characterized, and the development of sustained ocular hypertension could adversely affect ...
Bracha, Peter, Cantor, Louis B., Ciulla, Thomas A., Moore, Nicholas A., WuDunn, Darrell   +4 more
core   +1 more source

Comparison of Intravitreal Anti-VEGF Agents With Laser Photocoagulation for Retinopathy of Prematurity of 1,627 Eyes in China

Frontiers in Medicine, 2022
PurposeTo compare the efficacies and treatment outcomes of intravitreal anti-VEGF agents and laser therapy in retinopathy of prematurity (ROP).MethodsA retrospective, non-randomized, comparative study of patients diagnosed with type 1 ROP or aggressive ...
Dandan Linghu, Dandan Linghu, Dandan Linghu, Yong Cheng, Yong Cheng, Yong Cheng, Xuemei Zhu, Xuemei Zhu, Xuemei Zhu, Xun Deng, Xun Deng, Xun Deng, Hong Yin, Hong Yin, Hong Yin, Yanrong Jiang, Yanrong Jiang, Yanrong Jiang, Mingwei Zhao, Mingwei Zhao, Mingwei Zhao, Xiaoxin Li, Xiaoxin Li, Xiaoxin Li, Xiaoxin Li, Jianhong Liang, Jianhong Liang, Jianhong Liang   +27 more
doaj   +1 more source